CRL
HEALTHCARECharles River Laboratories
AI Insight
What's Moving CRL Today?
No stock-specific AI insight has been generated for CRL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$144.26$228.88
$186.60
Fundamentals
Market Cap$8.7B
P/E Ratio—
EPS$-3.70
Dividend Yield—
Dividend / Share—
ROE-5.9%
Profit Margin-4.6%
Debt / Equity—
Trading
Volume632K
Avg Volume (10D)—
Shares Outstanding48.2M
CRL News
73 articles- 2x Valuation Gap: BIO vs. CRL — Who’s Wrong?NAI500·Jun 24, 2026
- Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?Motley Fool·Jun 22, 2026
- How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?Barchart.com·Jun 22, 2026
- Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And UpgradeSimply Wall Street·Jun 21, 2026
- Charles River collaborates with Lilly TuneLab platformHospitalmanagement·Jun 19, 2026
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing ExpertiseBioSpace·Jun 19, 2026
- Morgan Stanley sees writing on wall for key drug research stocksThe Street·Jun 19, 2026
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing ExpertiseBusiness Wire·Jun 18, 2026
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing ExpertiseYahoo Finance Singapore·Jun 18, 2026
- What Charles River Laboratories (CRL)'s Morgan Stanley Upgrade Means For ShareholdersSimply Wall Street·Jun 17, 2026
- Charles River Labs Stock - Background and strategy snapshotAD HOC NEWS·Jun 17, 2026
- Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $220.29, Implies 19% UpsideTradingView·Jun 17, 2026
- Stocks Mixed Ahead of FOMC Meeting ResultsBarchart·Jun 17, 2026
- Stocks Supported by Chip Stock Strength and Strong US Retail SalesBarchart·Jun 17, 2026
- Lyft upgraded, Leidos downgraded: Wall Street's top analyst callsYahoo Finance·Jun 17, 2026
- Morgan Stanley favors Charles River Over IQVIA in CRO sector resetYahoo Finance·Jun 17, 2026
- Here Are Wednesday’s Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More24/7 Wall St.·Jun 17, 2026
- 1 S&P 500 Stock on Our Buy List and 2 We Brush OffYahoo Finance·Jun 16, 2026
- LH vs. CRL: Which Stock Is the Better Value Option?Yahoo Finance·Jun 15, 2026
- Charles River Labs (CRL) Pulled Back Due to AI Disruption FearsYahoo Finance·Jun 12, 2026
- Is It Time To Reassess Danaher (DHR) After Recent Share Price Recovery?Simply Wall Street·Jun 11, 2026
- Reasons Why You Should Hold Charles River Stock in Your PortfolioYahoo Finance·Jun 10, 2026
- Assessing Charles River Laboratories (CRL) Valuation After Recent Share Recovery And Conflicting Fair Value SignalsSimply Wall Street·Jun 9, 2026
- Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Incyte (INCY) and Pfizer (PFE)The Globe and Mail·Jun 9, 2026
- Charles River (NYSE: CRL) director James C. Foster reports 366,722-share gift and trust transfersStock Titan·Jun 8, 2026
- CRL (CRL) CEO shifts 6,772 shares via bona fide gifts, keeps large stakeStock Titan·Jun 8, 2026
- How Investors Are Reacting To Medpace Holdings (MEDP) Executive Shakeup Amid Securities Class Action SurgeSimply Wall Street·Jun 8, 2026
- Can Charles River’s Portfolio Divestitures and “Pathway to Purpose” Strategy Reframe the CRL Investment Narrative?Simply Wall Street·Jun 5, 2026
- Can Charles River’s Portfolio Divestitures and “Pathway to Purpose” Strategy Reframe the CRL Investment Narrative?Simply Wall Street·Jun 5, 2026
- Assessing Charles River Laboratories (CRL) Valuation After Mixed Returns And Contrasting Undervaluation SignalsYahoo Finance·Jun 4, 2026
- The Zacks Analyst Blog Highlights Stantec, CBIZ and Charles RiverYahoo Finance·Jun 4, 2026
- Zacks Industry Outlook Highlights Stantec, CBIZ and Charles RiverYahoo Finance·Jun 4, 2026
- Charles River (CRL) director awarded 422 restricted stock units as feesStock Titan·Jun 4, 2026
- CRL (CRL) CFO Glenn Coleman receives 6,640-share equity grant at $180.71Stock Titan·Jun 2, 2026
- Charles River Laboratories to Present at William Blair and Jefferies ConferencesYahoo Finance·Jun 1, 2026
- Here Are Friday’s Top Wall Street Analyst Research Calls: Best Buy, Cogent Communications, Dell Technologies, EPAM Systems, Federal Realty, Gap, Snowflake, Viper Energy, and More247 Wall St·May 29, 2026
- Are Wall Street Analysts Bullish on Charles River Laboratories Stock?Barchart·May 26, 2026
- Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services?Yahoo Finance·May 24, 2026
Price Data
Open$182.21
Previous Close$186.60
Day High$187.64
Day Low$181.53
52 Week High$228.88
52 Week Low$144.26
52-Week Range
$144.26$228.88
$186.60
Fundamentals
Market Cap$8.7B
P/E Ratio—
EPS$-3.70
Dividend Yield—
Dividend / Share—
ROE-5.9%
Profit Margin-4.6%
Debt / Equity—
Trading
Volume632K
Avg Volume (10D)—
Shares Outstanding48.2M
About Charles River Laboratories
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeCommon Stock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—